Free Consultation: 800-601-1616

Fen Phen

The attorneys of Baldante & Rubenstein are representing individuals who took Fen-Phen (fenflurarmine/phentermine), an anti-obesity treatment, and developed primary pulmonary hypertension (PPH) and heart valve problems.

On September 15, 1997, American Home Products Corporation (“AHP”) withdrew the diet drugs Pondimin® and Redux™ from the market. These drugs had been commonly prescribed by physicians alone and/or in combination with other prescription drugs (specifically, Phentermine) for weight loss. The combination of drugs was popularly known as “Fen-Phen.” Baldante & Rubenstein, P.C. represents individuals who have ingested Pondimin® and/or Redux™, alone, or in combination with phentermine, and filed individual lawsuits and class actions in federal and state courts against AHP and others, alleging that the use of the diet drugs has caused the individuals personal injury. The firm also represents individuals suffering from PPH, a serious pulmonary condition that has been associated with the Diet Drug medications. Baldante & Rubenstein, P.C. partner, Martin Rubenstein has been deeply involved in the class action and individual claim litigation, including the New Jersey Medical Monitoring Class Action trial that took place during the summer of 1999. It is widely regarded that the trial of the New Jersey Diet Drug Medical Monitoring Class Action was a driving force in bringing about the national settlement with AHP. Mr. Rubenstein was a member of the trial team that went to trial in the first heart valve fen phen case in the state of Pennsylvania and which ultimately helped to pave the way for settlement of many individual fen phen claims throughout the country. On October 7, 1999 a nationwide class action settlement was announced in which American Home Products, subject to Court approval, agreed to pay up to $4.83 Billion to resolve medical screening, medical areas, monitoring, refund and bodily damage claims of Pondimin (fenfluramine) and Redux (dexfenfluramine). The terms of the settlement established several important deadlines for consumers to act to preserve their rights for a settled claim, or to preserve their opt-out option. The settlement has received final judicial approval through the appellate courts, thus it is very important for all consumers who believe that they have been injured by Redux™ and/or Pondimin® to take immediate steps to preserve their legal rights.

If you or a loved one took Fen-Phen, and was diagnosed with primary pulmonary hypertension and heart valve problems, please immediately call the attorneys of Baldante & Rubenstein so that we can provide a timely free consultation for you, properly investigate your claim, and obtain justice for you from the responsible party.